ReviewWorld journal of gastroenterology2018
Multidisciplinary approach for post-liver transplant recurrence of hepatocellular carcinoma: A proposed management algorithm.
Review in World journal of gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 82 citations in OpenAlex.
- Asian Pacific Association for the Study of the Liver clinical practice guidelines on liver transplantation.Hepatology international · 2024Guideline
- PD-L1Technology in cancer research & treatmentTrial
- Systemic Treatment for Hepatocellular Carcinoma Recurrence After Liver Transplantation.Current oncology (Toronto, Ont.) · 2026Review
- Predicting and Managing Hepatocellular Carcinoma Recurrence After Liver Transplant: A Single-Center Experience 2012-2024.Cancers · 2026Article
- China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition).Liver cancer · 2025Article
- Recurrence of Hepatocellular Carcinoma After Liver Transplantation: The Blind Spot of HCC Management.United European gastroenterology journal · 2025Review
- Deep learning for hepatocellular carcinoma recurrence before and after liver transplantation: a multicenter cohort study.Scientific reports · 2025Article
- Renal metastasis of hepatocellular carcinoma after living donor liver transplantation.IJU case reports · 2025Article
- PET/MRI: pictorial review of hepatobiliary and pancreatic applications.Abdominal radiology (New York) · 2025Review
- Stereotactic radiation therapy for post-transplant systemic recurrence of hepatocellular carcinoma: safety, efficacy and a nomogram predicting overall survival.Frontiers in oncology · 2025Article
- Chinese guidelines for minimally invasive donor hepatectomy in living donor liver transplantation (2024 edition).Hepatobiliary surgery and nutrition · 2024Review
- Challenges related to clinical decision-making in hepatocellular carcinoma recurrence post-liver transplantation: Is there a hope?World journal of transplantation · 2024Review
- PVALB Was Identified as an Independent Prognostic Factor for HCC Closely Related to Immunity, and Its Absence Accelerates Tumor Progression by Regulating NK Cell Infiltration.Journal of hepatocellular carcinoma · 2024Article
- Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition).Liver cancer · 2023Article
- Ablative strategies for recurrent hepatocellular carcinoma.World journal of hepatology · 2023Review
- Usefulness of PIVKA-II for monitoring after liver transplantation in patients with hepatocellular carcinoma.Scientific reports · 2023Article
- Potential use of multikinase inhibitors in immunosuppressed patients with malignancies including thyroid cancer.Cancer medicine · 2022Review
- Therapeutic strategies for post-transplant recurrence of hepatocellular carcinoma.World journal of gastroenterology · 2022Review
- Impact of Tumour Biology on Outcomes of Radical Therapy for Hepatocellular Carcinoma Oligo-Recurrence after Liver Transplantation.Journal of clinical medicine · 2022Article
- Frontline therapy for advanced hepatocellular carcinoma: an update.Therapeutic advances in gastroenterology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A large number of liver transplants have been performed for hepatocellular carcinoma (HCC), and recurrence is increasingly encountered. The recurrence of HCC after liver transplantation is notoriously difficult to manage. We hereby propose multi-disciplinary management with a systematic approach. The patient is jointly managed by the transplant surgeon, physician, oncologist and radiologist. Immunosuppressants should be tapered to the lowest effective dose to protect against rejection. The combination of a mammalian target of rapamycin inhibitor with a reduced calcineurin inhibitor could be considered with close monitoring of graft function and toxicity. Comprehensive staging can be performed by dual-tracer positron emission tomography-computed tomography or the combination of contrast computed tomography and a bone scan. In patients with disseminated recurrence, sorafenib confers survival benefits but is associated with significant drug toxicity. Oligo-recurrence encompasses recurrent disease that is limited in number and location so that loco-regional treatments convey disease control and survival benefits. Intra-hepatic recurrence can be managed with graft resection, but significant operative morbidity is expected. Radiofrequency ablation and stereotactic body radiation therapy (SBRT) are effective alternative strategies. In patients with more advanced hepatic disease, regional treatment with trans-arterial chemoembolization or intra-arterial Yttrium-90 can be considered. For patients with extra-hepatic oligo-recurrence, loco-regional treatment can be considered if practical. Patients with more than one site of recurrence are not always contraindicated for curative treatments. Surgical resection is effective for patients with pulmonary oligo-recurrence, but adequate lung function is a pre-requisite. SBRT is a non-invasive and effective modality that conveys local control to pulmonary and skeletal oligo-recurrences.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.